Physician profile
Cynthia Haden Wright
NPI 1417945668
$3,938.12
in general payments reported to CMS, 2019-2025
22 companies · $303 in 2025
The $303 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $775 · 2020: $344 · 2021: $708 · 2022: $746 · 2023: $585 · 2024: $477 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,365.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,412.61 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $916.02 | 2019-2024 | Creon, Skyrizi, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $426.46 | 2019-2025 | Entyvio, Gattex |
| Celgene Corporation | $256.40 | 2021-2024 | Zeposia |
| Pfizer INC. | $195.86 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $119.64 | 2022-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $97.44 | 2022-2025 | Dupixent |
| Genzyme Corporation | $75.49 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $74.93 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $63.64 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $55.14 | 2020-2024 | Linzess |
| Ipsen Biopharmaceuticals, INC | $48.42 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $37.22 | 2022 | |
| Braintree Laboratories, INC. | $31.34 | 2023 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $30.39 | 2024 | Dificid |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $25.48 | 2019 | |
| Redhill Biopharma INC. | $23.40 | 2021 | |
| Alexion Pharmaceuticals, INC. | $12.54 | 2019 | |
| Evoke Pharma, INC. | $12.46 | 2022 | |
| Janssen Biotech, INC. | $12.22 | 2019 | |
| Allergan, INC. | $11.02 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$44,139.08 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.